Table 2.
Characteristics of patients with FL receiving first-line treatment in the WCM cohort (n = 196), MER cohort (n = 615), and LEO cohort (n = 583)
| Variables | WCM cohort* | MER cohort | LEO cohort† | |||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Age‡ | 62.6 ± 0.9 | 58.4 ± 0.5 | 59.5 ± 0.5 | |||
| Sex | ||||||
| Male | 95 | 48.5 | 329 | 53.5 | 293 | 50.3 |
| Female | 101 | 51.5 | 286 | 46.5 | 290 | 49.7 |
| Race | ||||||
| White | 156 | 79.6 | 546 | 88.8 | 510 | 87.5 |
| Other | 13 | 6.6 | 10 | 1.6 | 64 | 11.0 |
| Unknown | 27 | 13.8 | 59 | 9.6 | 9 | 1.5 |
| Ethnicity | ||||||
| Non-Hispanic | 159 | 81.1 | 492 | 80.0 | 507 | 87.0 |
| Hispanic | 19 | 9.7 | 9 | 1.5 | 63 | 10.8 |
| Unknown | 18 | 9.2 | 114 | 18.5 | 13 | 2.2 |
| Ann Arbor stage | ||||||
| II | 26 | 13.3 | 105 | 17.1 | 82 | 14.1 |
| III | 56 | 28.6 | 176 | 28.6 | 150 | 25.7 |
| IV | 46 | 23.5 | 325 | 52.8 | 321 | 55.1 |
| Unknown | 68 | 34.7 | 9 | 1.5 | 30 | 5.1 |
| Performance status | ||||||
| 0 | 143 | 73.0 | 403 | 65.5 | 338 | 58.0 |
| 1 | 51 | 26.0 | 178 | 28.9 | 177 | 30.4 |
| 2+ | 2 | 1.0 | 31 | 5.0 | 37 | 6.3 |
| Unknown | 0 | 0.0 | 3 | 0.5 | 31 | 5.3 |
| Splenic involvement | ||||||
| Yes | 89 | 14.5 | 128 | 22.0 | ||
| No | 522 | 84.9 | 420 | 72.0 | ||
| Unknown | 4 | 0.7 | 35 | 6.0 | ||
| Bulky disease | ||||||
| Yes | 8 | 4.1 | 56 | 9.1 | 76 | 13.0 |
| No | 119 | 60.7 | 548 | 89.1 | 447 | 76.7 |
| Unknown | 69 | 35.2 | 11 | 1.8 | 60 | 10.3 |
| WBC‡ | 7.3 ± 0.2 | 19.0 ± 11.5 | 7.7 ± 0.4 | |||
| ANC‡ | 4.8 ± 0.2 | 4.6 ± 0.1 | ||||
| Platelets‡ | 218 ± 8.5 | 241 ± 4.2 | 232 ± 3.8 | |||
| Hemoglobin‡ | 13.7 ± 0.1 | 13.4 ± 0.1 | 13.3 ± 0.1 | |||
| Creatinine‡ | 0.9 ± 0.02 | 1.0 ± 0.02 | 1.0 ± 0.01 | |||
| Bilirubin‡ | 0.7 ± 0.04 | 0.6 ± 0.01 | 0.6 ± 0.02 | |||
| Self-reported serious health conditions | ||||||
| Yes | 54 | 27.6 | 96 | 15.6 | 179 | 30.7 |
| No | 142 | 72.4 | 519 | 84.4 | 404 | 69.3 |
| Prior cancer diagnosis | ||||||
| Yes | 22 | 11.2 | 58 | 9.4 | 57 | 9.8 |
| Yes excluding exceptions§ | 22 | 3.6 | 37 | 6.3 | ||
| No | 174 | 88.8 | 557 | 90.6 | 526 | 90.2 |
| Number of first-line cycles‡ | 4.9 ± 0.19 | 6.0 ± 0.3 | ||||
| First-line treatmentǁ | ||||||
| CHOP-containing regimen | 168 | 27.3 | 131 | 22.5 | ||
| CVP-containing regimen | 143 | 23.3 | 4 | 0.7 | ||
| Bendamustine-containing regimen | 58 | 9.4 | 186 | 31.9 | ||
| Rituximab | 202 | 32.8 | 153 | 26.2 | ||
| Other | 44 | 7.2 | 109 | 18.7 | ||
| Time from diagnosis to treatment | ||||||
| ≤3 mo | 583 | 94.8 | 533 | 91.4 | ||
| ≤6 and >3 mo | 27 | 4.4 | 50 | 8.6 | ||
| >6 mo | 5 | 0.8 | 0 | 0.0 | ||
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone.
Blank entries correspond to not available data at time of chart review.
From LEO, 43 patients (7.4%) were enrolled from Cornell, 36 (6.2%) were from Emory, 37 (6.3%) were from Iowa, 143 (24.5%) were from Mayo Clinic, 181 (31.0%) were from MD Anderson, 49 (8.4%) were from Miami, 62 (10.6%) were from URMC, and 32 (5.5%) were from Washington University.
Categorical variables are presented as sample size (n) and column percentage (%); continuous variables are presented as mean ± standard error of the mean. Superscripts are added to the continuous variables.
Exceptions consist of non-melanoma skin cancer (eg, squamous cell carcinoma, basal cell carcinoma), breast cancer, cervical cancer in situ, and uterine cancer in situ.
Other first-line treatments consist of acalabrutinib, ABVD, CEPP, EPOCH (with and without rituximab), lenalidomide, cyclophosphamide, chlorabucil, bortezomib, fludarabine, ibritumomab, obinutuzumab, methotrexate, and prednisone.